期刊文献+

胰腺癌细胞株对氟尿嘧啶存在固有不敏感性 被引量:3

Intrinsic Resistance of Pancreatic Cancer Cell Lines towards 5-Fluorouracil
下载PDF
导出
摘要 目的 研究胰腺癌细胞株是否对氟尿嘧啶 ( 5 - FU )具有固有或获得性不敏感。方法 用 SRB方法检测5 - FU对胰腺癌细胞株 As PC- 1、Capan- 1、Mia- Pa Ca- 2、Panc- 1和 T3 M4的毒性作用。结果  5 - FU对所有胰腺癌细胞株的 IC50 都很高 ,其中 Mia- Pa Ca- 2和 Panc- 1细胞株对 5 - FU最不敏感 ( IC50 =12 ,13 nmol/ L )。即使是在 5 - FU最敏感的 Capan- 1细胞株 ,其 IC50 仍相当高 ( 473 pm ol/ L)。这些细胞株对 5 - FU的 IC50 甚至高出其临床常用剂量给药时血浆药物浓度的 1~ 5 6倍。结论 大多数胰腺癌细胞株对 5 - FU固有不敏感 ,这些发现也许能作为临床上 5 - AIM To investigate whether the pancreatic cancer cells possess the intrinsic or acquired resistance to 5-fluorouracil(5-FU). METHODS The cytotoxic effects of 5-FU on AsPC-1, Capan-1, Mia-PaCa-2, Panc-1 and T3M4 pancreatic cancer cells were assessed by the sulforhodamine B protein assay (SRB). RESULTS The IC 50 of 5-FU in pancreatic cancer cell lines was exceedingly high. Panc-1 and Mia-PaCa-2 showed the highest resistance to 5-FU (IC 50= 12 and 13 μmol/L, respectively), and even in the most sensitive cell line, Capan-1, the IC 50 was still relatively high (473 pmol/L). These IC 50 were even much higher (1~56 times) than plasma concentrations when 5-FU was given to patients at a standard dosage. CONCLUSION Most of the pancreatic cancer cell lines are intrinsic resistant to 5-FU. These findings may represent one of the reasons why pancreatic cancer responds only poorly to 5-FU treatment in the clinical practice.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2002年第6期492-495,共4页 Journal of China Pharmaceutical University
基金 瑞士国家科学基金项目 ( No. 2 0 3/99/0 0 44)
关键词 氟尿嘧啶 敏感性 胰腺癌 化学治疗 细胞培养 细胞毒性 Fluorouracil Resistance Pancreatic cancer Chemotherapy Cell culture Cytotoxity
  • 相关文献

参考文献10

  • 1[1]Blaszkowsky L. Treatment of advanced and metastatic pancreatic cancer [J]. Surgery, 1998,124:143-150.
  • 2[2]Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-atlantic oncology program study [J]. J Clin Oncol, 1989,7: 425-432.
  • 3[3]Kollmannsberger C, Peters HD, Fink U. Chemotherapy in ad-vanced pancreatic adenocarcinoma [J]. Cancer Treat Rev, 1998,24:133-156.
  • 4[4]David-Beabes GL, Overman MJ, Petrofski JA, et al. Doxorubicin-resistant variant of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: Characterization of biochemical determinants of antineoplastic drug sensitivity [J]. Int J Oncol,2000,17:1077-1086.
  • 5[5]Keepers YP, Pizao PE, Peters GF, et al. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing [J]. Eur J Cancer,1991,27:897-900.
  • 6[6]Procházková A, Liu SL, Friess H,et al. Determination of 5-fluorouracil and 5-fluoro-2-deoxyuridine -5 -monophosphate in pancreatic cancer cell line and other biological material using capillary electrophoresis [J]. J Chromatography A, 916:215-224.
  • 7[7]Harstrick A, Gonzales A, Schleucher N,et al. Comparison be-tween short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance [J]. Anticancer Drugs,1998,9(7): 625-634.
  • 8[8]Heggi GD, Sommadossi JP, Cross DS, et al. Clinical pharma-cokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile[J]. Cancer Res,1987,47:2203-2206.
  • 9[9]Inaba M, Nave Y, Mitsuhashi J. Mechanisms for 5-flourouracil resistance in human colon cancer DLD-1 cells [J]. Biol Pharm,1998,21(6): 569-573.
  • 10[10]Litman T, Druley TE, Stein WD,et al. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance [J]. Cell Mol Life Sci,2001,58(7): 931-959.

同被引文献7

  • 1F奥斯伯 颜子颖译.精编分子生物学实验指南[M].北京:科学出版社,1998.671.
  • 2Procházková A,Liu SL,Friess H et al.Determination of 5-fluorouracil and 5-fluoro-2'-deoxyuridine-5'-monophosphate in pancreatic cancer cell line and other biological material using capillary electrophoresis.J Chromatogr A,2001;916(1~2):215~24
  • 3Black ME,Kokoris MS,Sabo P,et al.Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediate tumor cell killing[J].Cancer Res,2001,61(7):3022-3026.
  • 4Diana KH,Raj KV,John CO,et al.Comparison of effects of three different toxin genes and their levels of expression on cell growth and bystander effect In lung adenocarcinoma[J].Cancer Res,1996,56:1315-1323.
  • 5Freeman SM,Aboud CN,Whartenby KA,et al.The bystander effect:Tumor regression when a fraction of the tumor mass is genetically modified[J].Cancer Res,1993,53:5274-5278.
  • 6Chen SH,Chen XH,Wang Y,et al.Combination gene therapy for liver metastasis of colon carcinoma in vivo[J].Proc Natl Acad Sci USA,1995,92(7):2577-2581.
  • 7张世能,袁世珍.胞嘧啶脱氨酶基因治疗人胰腺癌的实验研究[J].中华医学杂志,2000,80(4):249-251. 被引量:6

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部